BC
ASMB icon

Bridgefront Capital’s Assembly Biosciences ASMB Stock Holding History

Bridgefront Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-845
Closed -$21K – 298
2022
Q1 		$21K Hold
845
– – 0.03% 250
2021
Q4 		$24K Hold
845
– – 0.02% 287
2021
Q3 		$35K Sell
845
-114
-12% -$4.78K 0.04% 296
2021
Q2 		$45K Buy
+959
New +$47.5K 0.02% 577
2021
Q1 		– Sell
-1,213
Closed -$88K – 667
2020
Q4 		$88K Buy
+1,213
New +$142K 0.03% 569

Other funds holding ASMB

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgefront Capital's ASMB Position: Q2 2022 in Review

Bridgefront Capital sold out of Assembly Biosciences (ASMB) in Q2 2022, closing a stake of 845 shares — an estimated $21K sold.

Bridgefront Capital first reported a position in ASMB in Q4 2020 and held it in 5 quarters. The position peaked at $88K in Q4 2020. 54 funds tracked by Wall St. Rank hold ASMB as of Q2 2022.

  • Bridgefront Capital reported no remaining Assembly Biosciences position as of Q2 2022 after selling out during the quarter.
  • Bridgefront Capital sold 845 Assembly Biosciences shares in Q2 2022, an estimated $21K.
  • Bridgefront Capital first reported a position in Assembly Biosciences in Q4 2020 and held it in 5 quarters.
  • Bridgefront Capital's Assembly Biosciences position peaked at $88K in Q4 2020.
  • 54 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2022.

Based on Bridgefront Capital's 13F filing for Q2 2022, filed 12 Aug 2022.